comparemela.com

Latest Breaking News On - Neoadjuvant treatment - Page 4 : comparemela.com

Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) with Chemotherapy as Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer at High Risk of Recurrence in Patients with Tumor Cell PD-L1 Expre

Recommendation based on results from the Phase 3 CheckMate -816 trial, in which Opdivo with chemotherapy demonstrated improved event-free survival and pathologic complete response compared to. | May 26, 2023

South koreaUnited statesBristol myers squibbAbderrahim oukessouCommittee for medicinal products human useOno pharmaceutical coEuropean commissionEuropean lung cancer congressEuropean medicines agencyEuropean unionCompany opdivoBristol myers squibb receives positiveRecommending approvalNeoadjuvant treatmentResectable non small cell lung cancerHigh risk

Novel Therapy in Urothelial Carcinoma: An Evolving Treatment Landscape

Closing out their discussion on urothelial carcinoma, key opinion leaders share clinical pearls and excitement for the evolving treatment landscape.

Urothelial carcinomasUrothelial carcinomaBladder cancerUrothelial cancerNovel therapyCombination therapyCheckpoint inhibitorsTargeted therapyEnfortumab vedotinNeoadjuvant therapyNeoadjuvant treatmentAdjuvant therapyAdjuvant treatmentCheckmate 274Ambassador trialCirculating tumor dna

Novel Treatment Strategies in Muscle Invasive Bladder Cancer

A comprehensive review of novel treatment strategies in MIBC, including perioperative therapy, and respective ongoing clinical trials.

Urothelial carcinomasTreatment strategiesMuscle invasive bladder cancerBladder cancerUrothelial cancerUrothelial carcinomaNeoadjuvant therapyNeoadjuvant treatmentAdjuvant therapyAdjuvant treatmentEv 103Enfortumab vedotinTar 200Sunrise programSunrise 3

Clinical Trial Data With Perioperative Therapy in MIBC: HCRN GU 16-257

Shared insight on the combination of gemcitabine, cisplatin, and nivolumab in patients with muscle-invasive bladder cancer in the HCRN GU 16-257 trial.

Urothelial carcinomasTrial data with perioperative therapyBladder cancerUrothelial cancerUrothelial carcinomaNeoadjuvant therapyNeoadjuvant treatmentAdjuvant therapyAdjuvant treatmentHcrn gu 16 257Combination therapyClinical staging

Clinical Trial Data With Perioperative Therapy in MIBC: Bladder BRIDGister

Expert panelists reflect on the molecular subtyping of patients to predict response to neoadjuvant therapy in Bladder BRIDGister.

Urothelial carcinomasTrial data with perioperative therapyBladder cancerUrothelial cancerUrothelial carcinomaNeoadjuvant therapyNeoadjuvant treatmentBladder bridgisterBiomarker testingMolecular testing

vimarsana © 2020. All Rights Reserved.